Chimeric antigen receptor

Breakthrough CAR-T-Cell Therapy Offers Hope for Lupus Treatment

Recent breakthroughs in lupus treatment highlight the potential of CAR-T-cell therapy, previously used for cancer, to achieve complete remission in patients. This revolutionary approach has sparked hope for a possible cure, transforming the management of autoimmune diseases. Experts emphasize the need for continued research to explore innovative therapies that could change the future of lupus care.

Breakthrough CD7 CAR-T Cell Therapy Shows Promise for T-ALL Patients

The National University Health System in Singapore has announced groundbreaking results from a novel CAR-T cell therapy targeting CD7, offering new hope for patients with relapsed or refractory T-cell acute lymphoblastic leukaemia (T-ALL). This innovative treatment, developed in partnership with the National University of Singapore, modifies patients’ T cells to enhance immune responses against cancer cells, showing promising outcomes in clinical trials. With the potential to improve survival rates and quality of life, this therapy represents a significant advancement in precision medicine for aggressive leukaemia.

New CAR T-Cell Therapy Offers Hope to Lymphoma Patients

Learn about the promising new CAR T-Cell therapy offering hope to lymphoma patients who have not responded to traditional treatments. Discover how this innovative therapy is providing a potential cure for individuals like John Bell, who faced an aggressive form of lymphatic system cancer and found new hope through this groundbreaking treatment.

Promising Results in Asthma Treatment Using Engineered T Cells

Groundbreaking study in Nature Immunology shows promising results in treating asthma with engineered long-lived and multifunctional T cells. Research led by Gang Jin demonstrates durable remission of asthma in mice with a single infusion. This innovative approach offers hope for the future of asthma treatment and the potential of immunotherapy in managing respiratory diseases.

Zhejiang University Makes History with CAR-T Therapy for Childhood-Onset SLE

Zhejiang University makes history by applying CAR-T therapy for childhood-onset systemic lupus erythematosus (SLE), showcasing promising results in addressing severe autoimmune disorders. The groundbreaking milestone in March 2024 marks the world’s first application of CAR-T therapy in a pediatric SLE case, offering new hope for personalized medicine and targeted therapies in the field of autoimmune disorders.

Enobosarm Shows Promising Antitumor Activity in ER-Positive, HER2-Negative Advanced Breast Cancer

A recent study published in The Lancet Oncology has shown promising antitumor activity of enobosarm in patients with ER-positive, HER2-negative advanced breast cancer. The study assessed the activity and safety of enobosarm in women with previously treated locally advanced or metastatic breast cancer, with results showing potential benefits but also some drug-related adverse events. The study was funded by GTx, the original developer of enobosarm, and has implications for the potential role of androgen receptor modulation in cancer therapy.

CAR T Cells Show Potential in Treating Age-Related Diseases, Study Finds

Recent research led by Memorial Sloan Kettering Cancer Center and Cold Spring Harbor Laboratory has revealed the potential of Chimeric Antigen Receptor (CAR) T cells in treating diseases related to aging. The study suggests that these engineered immune cells could…

Breakthrough in Anti-Ageing Research

A recent breakthrough in anti-ageing research has uncovered a potential key to slowing down the ageing process, offering the prospect of a longer and healthier life. Published in Nature Aging, the study conducted by scientists in the USA has revealed…